RNAi Therapeutics Platform Progress at OTS 2021 Annual Meeting

29 Sep, 2021 RNAi Therapeutics Platform Progress at OTS 2021 Annual Meeting

We presented progress on our RNAi therapeutics platform efforts at the Oligonucleotide Therapeutics Society (OTS) 2021 Annual Meeting.

Read the press release

Harnessing RNAi for a New Class of Medicines – John Maraganore

Expanding the Reach of RNAi Therapeutics – Kirk Brown

Development of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 – Pushkal Garg

Dose-Related and Prolonged Reductions in Blood Pressure with a RNAi Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results from a Phase 1 Study with Zilebesiran (ALN-AGT01) – Stephen Huang

Progress of RNAi in Extrahepatic Tissues – Haiyan Peng